BACKGROUND: There has been recent interest in the possible role of reperfusion-induced @entity32 with @entity528 after @entity64 . Enlimomab, a @entity19 @entity8024 ( @entity8024 ) antibody, reduces leukocyte adhesion and @entity1188 size in experimental @entity64 studies. The purpose of the current clinical trial was to evaluate the use of enlimomab after @entity385 . METHODS: A total of 625 @entity1 with @entity385 were randomized to receive either enlimomab (n = 317) or placebo (n = 308) within 6 hours of @entity64 onset. Treatment was given over 5 days. @entity1 were evaluated at baseline and on days 5 and 90 after initiation of treatment; long-term assessments were carried out after 6 and 12 months. The primary efficacy endpoint was the response to therapy at 90 days on the Modified Rankin Scale; other endpoints included Barthel Index (BI) and NIH @entity64 Scale and survival. RESULTS: At day 90, the Modified Rankin Scale score was worse in @entity1 treated with enlimomab than with placebo (p = 0.004). Fewer @entity1 had symptom-free recovery on enlimomab than placebo (p = 0.004), and more died (22.2 versus 16.2%). The negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment (p = 0.005). There were significantly more adverse events with enlimomab treatment than placebo, primarily infections and @entity221 . @entity1 experiencing @entity221 were more likely to have a poor outcome or die. CONCLUSIONS: The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for @entity385 in the model studied and, indeed, may significantly worsen @entity64 outcome.

Use of anti-ICAM-1 therapy in @entity385 : results of the Enlimomab Acute XXXX Trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'Stroke'] @entity19 :: ('10090', 'Species') :: ['murine'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct'] @entity8024 :: ('15894(Tax:10090)', 'Gene') :: ['ICAM-1', 'intercellular adhesion molecule-1'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever'] @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal injury'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity64 :: (MESH:D020521,Disease) :: ['Stroke']
